Welcome to CSL Seqirus

We stand on the front line with partners in public health discovering, developing, and delivering pioneering seasonal and pandemic vaccine solutions to safeguard people and communities across the world.

Female_Closeup2_Horiz

Seasonal Influenza

CSL Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of seasonal influenza globally, with extensive research and advanced manufacturing expertise.

We utilise both cell-based and egg-based technologies for influenza vaccine production and have developed the only adjuvanted seasonal influenza vaccine for elderly populations. Our scientists continue to optimise these innovative technologies while working on longer-term transformational approaches to influenza protection.

Report a Suspected Adverse Event

CSL Seqirus actively gathers information on adverse drug events and reactions to safeguard product safety. This enables us to thoroughly investigate, assess, and report such events to the relevant regulatory authorities to ensure the well-being of all patients. If you experience any side effects from CSL Seqirus products, we strongly urge you to report them as soon as possible using the contact details provided below. Your feedback plays a crucial role in helping us maintain the highest safety standards for our products.

To report adverse drug events/adverse reactions, please use the following link:

 

Adverse events may also be reported to CSL Seqirus via seqirus@eu.propharmagroup.com.

Please note that when you report an adverse drug event/adverse reaction, we will collect your relevant personal information. For more information on how we process your personal information please refer to our CSL Global Privacy Policy.

NRD-NOPR-25-0005 June 2025